这项发表在《自然》上的研究，通过层层递进的逻辑，为我们解开了一个长期存在的谜题。它确立了“肠道-肿瘤轴”中T细胞可塑性的核心地位，提出了“抗原模拟”作为治疗策略的可行性，并强调了微生物种类的选择至关重要。

Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.

Background RNA 5-methylcytosine (m5C) has emerged as a critical epigenetic regulator in cancer biology, yet its role in the ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target tumors. Despite their initial clinical success, many patients eventually ...

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

Marengo Therapeutics, Inc., a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets of the germline TCR ...

Equivalence of Ina, an AI-based nutrition platform, to human dietitians for counseling patients with cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...